Internal Reference Number: FOI_6630
Date Request Received: 13/06/2022 00:00:00
Date Request Replied To: 20/06/2022 00:00:00
This response was sent via: By Email
Request Summary: Lung Cancer medication
Request Category: Companies
| Question Number 1: In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with: • Afatinib • Alectinib • Amivantamab • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Brigatinib • Ceritinib • Crizotinib • Dacomitinib • Dabrafenib with Trametinib • Durvalumab • Erlotinib • Gefitinib • Lorlatinib • Mobocertinib • Nintedanib with Docetaxel • Nivolumab • Osimertinib • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Pemetrexed with Carboplatin/Cisplatin • Sotorasib • Tepotinib • Vinorelbine with Carboplatin/Cisplatin • Any other active systemic anti-cancer therapy (SACT) • Palliative care only | |
| Answer To Question 1: • Afatinib - 0 • Alectinib - Less than 5 • Amivantamab - 0 • Atezolizumab monotherapy - Less than 5 • Atezolizumab with chemotherapy - Less than 5 • Brigatinib - 0 • Ceritinib - 0 • Crizotinib - 0 • Dacomitinib - 0 • Dabrafenib with Trametinib - 0 • Durvalumab - Less than 5 • Erlotinib - 0 • Gefitinib - Less than 5 • Lorlatinib - Less than 5 • Mobocertinib - 0 • Nintedanib with Docetaxel - 0 • Nivolumab - 0 • Osimertinib -1 1 • Pembrolizumab monotherapy -12 • Pembrolizumab with chemotherapy - 6 • Pemetrexed with Carboplatin/Cisplatin - 8 • Sotorasib - 0 • Tepotinib - 0 • Vinorelbine with Carboplatin/Cisplatin - Less than 5 • Any other active systemic anti-cancer therapy (SACT) - 0 • Palliative care only - unable to provide information | |
| Question Number 2: In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs: • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Durvalumab • Nivolumab • Osimertinib • Pembrolizumab (Keytruda) Mono • Pembrolizumab (Keytruda) with Chemotherapy • Tepotinib • Other active systemic anti-cancer therapy (SACT) • Palliative care only | |
| Answer To Question 2: • Atezolizumab monotherapy - Less than 5 • Atezolizumab with chemotherapy - Less than 5 • Durvalumab - Less than 5 • Nivolumab - 0 • Osimertinib - 0 • Pembrolizumab (Keytruda) Mono - Less than 5 • Pembrolizumab (Keytruda) with Chemotherapy - 0 • Tepotinib - 0 • Other active systemic anti-cancer therapy (SACT) - 0 • Palliative care only - unable to provide information | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
